Dimensional Fund Advisors LP Grows Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Dimensional Fund Advisors LP boosted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.6% in the 2nd quarter, HoldingsChannel reports. The fund owned 1,239,502 shares of the medical equipment provider’s stock after acquiring an additional 19,071 shares during the period. Dimensional Fund Advisors LP’s holdings in Lantheus were worth $99,525,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of LNTH. Daiwa Securities Group Inc. acquired a new position in shares of Lantheus during the first quarter worth $1,269,000. Nordea Investment Management AB increased its holdings in shares of Lantheus by 42.6% in the 1st quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock valued at $2,932,000 after acquiring an additional 14,147 shares during the last quarter. Hancock Whitney Corp raised its position in shares of Lantheus by 265.6% during the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock worth $1,254,000 after acquiring an additional 14,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in Lantheus during the second quarter worth approximately $290,000. Finally, Pitcairn Co. boosted its holdings in Lantheus by 117.0% in the first quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider’s stock valued at $521,000 after purchasing an additional 4,509 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Lantheus

In other news, CAO Andrea Sabens sold 341 shares of the stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the transaction, the chief accounting officer now directly owns 62,216 shares of the company’s stock, valued at approximately $7,661,900.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now directly owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,852 shares of company stock valued at $3,922,001. 1.50% of the stock is owned by corporate insiders.

Lantheus Trading Up 0.4 %

NASDAQ:LNTH opened at $111.76 on Wednesday. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. The stock’s 50 day simple moving average is $105.14 and its 200-day simple moving average is $85.08. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The firm has a market cap of $7.75 billion, a P/E ratio of 17.06 and a beta of 0.50.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The firm had revenue of $394.10 million for the quarter, compared to analysts’ expectations of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.40 EPS. Equities analysts anticipate that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on LNTH. Truist Financial reduced their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Redburn Atlantic assumed coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. B. Riley raised their price objective on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Leerink Partners boosted their target price on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Finally, JMP Securities dropped their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 1st. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.